MIN 101 - Minoryx Therapeutics
Alternative Names: MIN-101 Minoryx TherapeuticsLatest Information Update: 25 Oct 2021
At a glance
- Originator IDIBELL
- Developer IDIBELL; Minoryx Therapeutics
- Class Small molecules; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Adrenoleucodystrophy
Most Recent Events
- 04 Jan 2017 Discontinued - Preclinical for Adrenoleucodystrophy in Spain (PO) (Minoryx Therapeutics pipeline, January 2017)